Moscoso Galán, IsabelCebro Márquez, MaríaMartínez Gómez, ÁlvaroAbou Jokh Casas, ChariganMartínez Monzonís, María AmparoMartínez Sande, José LuisGonzález Melchor, LailaGarcía Seara, JavierFernández López, Xesús AlberteMoraña Fernández, SandraGonzález Juanatey, José RamónRodríguez Mañero, MoisésLage Fernández, Ricardo2024-02-012024-02-012022Moscoso, I.; Cebro-Márquez, M.; Martínez-Gómez, Á.; Abou-Jokh, C.; Martínez-Monzonís, M.A.; Martínez-Sande, J.L.; González-Melchor, L.; García-Seara, J.; Fernández-López, X.A.; Moraña-Fernández, S.; et al. Circulating miR-499a and miR-125b as Potential Predictors of Left Ventricular Ejection Fraction Improvement after Cardiac Resynchronization Therapy. Cells 2022, 11, 271. https://doi.org/10.3390/cells11020271http://hdl.handle.net/10347/32181Cardiac resynchronization therapy represents a therapeutic option for heart failure drug-refractory patients. However, due to the lack of success in 30% of the cases, there is a demand for an in-depth analysis of individual heterogeneity. In this study, we aimed to evaluate the prognostic value of circulating miRNA differences. Responder patients were defined by a composite endpoint of the presence of left ventricular reverse remodelling (a reduction ≥15% in telesystolic volume and an increment ≥10% in left ventricular ejection fraction). Circulating miRNAs signature was analysed at the time of the procedure and at a 6-month follow-up. An expression analysis showed, both at baseline and at follow-up, differences between responders and non-responders. Responders presented lower baseline expressions of miR-499, and at follow-up, downregulation of miR-125b-5p, both associated with a significant improvement in left ventricular ejection fraction. The miRNA profile differences showed a marked sensitivity to distinguish between responders and non-responders. Our data suggest that miRNA differences might contribute to prognostic stratification of patients undergoing cardiac resynchronization therapy and suggest that preimplant cardiac context as well as remodelling response are key to therapeutic successeng© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).Atribución 4.0 Internacionalhttp://creativecommons.org/licenses/by/4.0/Heart failureAdverse remodellingCardiac resynchronization therapymicroRNAsCardiac biomarkerCardiac therapeutic targetjournal article10.3390/cells110202712073-4409open access